Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

French MBE company Riber has reported its results for the first half of 2025 with revenues of €10.7m, down 22 percent ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

"While U.S. POINTER was designed and powered as a head-to-head comparison of the two interventions, and a statistically ...